Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Sasagu Kurozumi, Ayaka Katayama, Ken Shirabe, Jun Horiguchi and Emad A. Rakha _

PDF  |  How to cite  |  Order a Reprint

Oncotarget. 2021; 12:2302-2304. https://doi.org/10.18632/oncotarget.28007

Metrics: PDF 575 views  |   ?  

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28007